January 12th- “Genomically Smoldering” Myeloma Really Smoldering? CME Congresses . January 12th- “Genomically Smoldering” Myeloma Really Smoldering? January 5th- Linvoseltamab in relapsed refractory multiple myeloma: Durable Responses and Real-World Relevance CME Congresses . January 5th- Linvoseltamab in relapsed refractory multiple myeloma: Durable Responses and Real-World Relevance December 31st- Post-Transplant Cyclophosphamide in HLA-Matched Peripheral Blood Transplantation CME Congresses . December 31st- Post-Transplant Cyclophosphamide in HLA-Matched Peripheral Blood Transplantation December 29th- Dr. Richard Dillon and Dr. Jad Othman- Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML CME Congresses . December 29th- Dr. Richard Dillon and Dr. Jad Othman- Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML December 23rd- PRECISION-T: Are We Entering a New Era of GVHD Prophylaxis? CME Congresses . December 23rd- PRECISION-T: Are We Entering a New Era of GVHD Prophylaxis? December 19th- BEYOND the Horizon: Long-Term Luspatercept Data in non–transfusion-dependent β-thalassemia CME Congresses . December 19th- BEYOND the Horizon: Long-Term Luspatercept Data in non–transfusion-dependent β-thalassemia December 18th- ASH 2025 Highlight: Stem Cell Boost for CAR-T–Related Hematologic Toxicity in multiple myeloma: Real-World Evidence CME Congresses . December 18th- ASH 2025 Highlight: Stem Cell Boost for CAR-T–Related Hematologic Toxicity in multiple myeloma: Real-World Evidence December 16th- ASH 2025 Highlight- Menin Inhibitors AML Update CME Congresses . December 16th- ASH 2025 Highlight- Menin Inhibitors AML Update December 12th- ASH 2025 Spotlight: BRUIN CLL-313 Pirtobrutinib Moves to the Frontline CME Congresses . December 12th- ASH 2025 Spotlight: BRUIN CLL-313 Pirtobrutinib Moves to the Frontline December 10th- ASH 2025 Spotlight: Sustained MRD as a Transformative Endpoint in Transplant-Ineligible Myeloma- Insights from the BENEFIT Phase 3 Study CME Congresses . December 10th- ASH 2025 Spotlight: Sustained MRD as a Transformative Endpoint in Transplant-Ineligible Myeloma- Insights from the BENEFIT Phase 3 Study Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18
